A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors

Clinical trial NCT07124793 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07124793
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

Start date: 2025-08-31
Primary completion: 2026-09-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.